NASDAQ:HTBX - Heat Biologics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $1.96 +0.07 (+3.70 %) (As of 09/21/2018 04:00 PM ET)Previous Close$1.89Today's Range$1.87 - $1.9652-Week Range$1.09 - $7.90Volume127,658 shsAverage Volume957,219 shsMarket Capitalization$43.25 millionP/E RatioN/ADividend YieldN/ABeta1.05 Company ProfileDiscussionAnalyst RatingsChartEarnings HistoryFinancialsInsider TradesHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Heat Biologics, Inc., a biopharmaceutical company, focuses on developing approaches to activate and co-stimulate a patient's immune system against cancer in the United States. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors hot and be administered in combination with checkpoint inhibitors and other immuno-modulators to enhance clinical effectiveness. Its TCAP product candidates include ImPACT platform technology that develops product candidates consist of live, allogeneic off-the-shelf genetically-modified, and irradiated human cancer cells; and Combination Pan-antigen Cytotoxic Therapy, a dual-acting immunotherapy designed to deliver T-cell activation and enhanced, and T-cell specific co-stimulation in a single treatment. The company is developing HS-110 that is in Phase 2 clinical trial in combination with Bristol-Myers Squibb's nivolumab (Opdivo) for the treatment of non-small cell lung cancer. Its preclinical trial product candidates include HS-130 for the treatment of non-muscle invasive bladder cancer; and PTX-35 and PTX-15 for treating tumors and hematologic malignancies. The company was founded in 2008 and is headquartered in Durham, North Carolina. Receive HTBX News and Ratings via Email Sign-up to receive the latest news and ratings for HTBX and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical SymbolNASDAQ:HTBX CUSIPN/A Webwww.heatbio.com Phone919-240-7133 Debt Debt-to-Equity RatioN/A Current Ratio3.88 Quick Ratio3.88 Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$1.51 million Price / Sales30.02 Cash FlowN/A Price / CashN/A Book Value$1.38 per share Price / Book1.42 Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-11,840,000.00 Net Margins-437.62% Return on Equity-116.28% Return on Assets-55.33% Miscellaneous Employees19 Outstanding Shares23,130,000Market Cap$43.25 million Heat Biologics (NASDAQ:HTBX) Frequently Asked Questions What is Heat Biologics' stock symbol? Heat Biologics trades on the NASDAQ under the ticker symbol "HTBX." When did Heat Biologics' stock split? How did Heat Biologics' stock split work? Heat Biologics's stock reverse split before market open on Monday, January 22nd 2018. The 1-10 reverse split was announced on Friday, January 19th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Friday, January 19th 2018. An investor that had 100 shares of Heat Biologics stock prior to the reverse split would have 10 shares after the split. How were Heat Biologics' earnings last quarter? Heat Biologics Inc (NASDAQ:HTBX) issued its earnings results on Tuesday, August, 14th. The biopharmaceutical company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.18) by $0.09. The biopharmaceutical company had revenue of $1.14 million for the quarter, compared to the consensus estimate of $1.11 million. Heat Biologics had a negative net margin of 437.62% and a negative return on equity of 116.28%. View Heat Biologics' Earnings History. When is Heat Biologics' next earnings date? Heat Biologics is scheduled to release their next quarterly earnings announcement on Monday, November, 12th 2018. View Earnings Estimates for Heat Biologics. What price target have analysts set for HTBX? 3 brokerages have issued 1 year price targets for Heat Biologics' shares. Their predictions range from $6.00 to $11.00. On average, they expect Heat Biologics' share price to reach $8.50 in the next year. This suggests a possible upside of 338.1% from the stock's current price. View Analyst Price Targets for Heat Biologics. What is the consensus analysts' recommendation for Heat Biologics? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Heat Biologics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Heat Biologics. Who are some of Heat Biologics' key competitors? Some companies that are related to Heat Biologics include Zomedica Pharmaceuticals Corp (NYSEAMERICAN) (ZOM), REDHILL BIOPHAR/S (RDHL), Molecular Templates (MTEM), Calithera Biosciences (CALA), Aldeyra Therapeutics (ALDX), Immune Design (IMDZ), VERONA PHARMA P/S (VRNA), Syndax Pharmaceuticals (SNDX), Avadel Pharmaceuticals (AVDL), Sesen Bio (SESN), BioDelivery Sciences International (BDSI), Eleven Biotherapeutics (EBIO), Tetraphase Pharmaceuticals (TTPH), Spring Bank Pharmaceuticals (SBPH) and Cerecor (CERC). Who are Heat Biologics' key executives? Heat Biologics' management team includes the folowing people: Mr. Jeffrey Alan Wolf, Founder, Chairman, CEO & Pres (Age 55)Ms. Ann A. Rosar, VP of Fin., Controller & Sec. (Age 66)Dr. Jeff T. Hutchins, Chief Scientific Officer & COO (Age 59)Dr. Justin Stebbing M.D., M.A., FRCP, FRCPath, Ph.D., Chief Medical Advisor and Member of Scientific & Clinical Advisory BoardColonel George E. Peoples Jr., M.D., FACS, Chief Medical Advisor Has Heat Biologics been receiving favorable news coverage? Headlines about HTBX stock have trended somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies negative and positive press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Heat Biologics earned a media and rumor sentiment score of 0.18 on Accern's scale. They also gave news coverage about the biopharmaceutical company an impact score of 46.57 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the near term. View Recent Headlines for Heat Biologics. Who are Heat Biologics' major shareholders? Heat Biologics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Northern Trust Corp (0.22%). View Institutional Ownership Trends for Heat Biologics. Which institutional investors are buying Heat Biologics stock? HTBX stock was acquired by a variety of institutional investors in the last quarter, including Northern Trust Corp. View Insider Buying and Selling for Heat Biologics. How do I buy shares of Heat Biologics? Shares of HTBX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Heat Biologics' stock price today? One share of HTBX stock can currently be purchased for approximately $1.94. How big of a company is Heat Biologics? Heat Biologics has a market capitalization of $43.25 million and generates $1.51 million in revenue each year. Heat Biologics employs 19 workers across the globe. How can I contact Heat Biologics? Heat Biologics' mailing address is 801 CAPITOLA DRIVE, DURHAM NC, 27713. The biopharmaceutical company can be reached via phone at 919-240-7133 or via email at [email protected] MarketBeat Community Rating for Heat Biologics (NASDAQ HTBX)Community Ranking: 2.9 out of 5 ( )Outperform Votes: 235 (Vote Outperform)Underperform Votes: 166 (Vote Underperform)Total Votes: 401MarketBeat's community ratings are surveys of what our community members think about Heat Biologics and other stocks. Vote "Outperform" if you believe HTBX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HTBX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 9/21/2018 by MarketBeat.com StaffFeatured Article: What is a Leveraged Buyout (LBO)?